

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

B16-F10-Luc2 [ATCC]

RRID:CVCL_A4CJ

Type: Cell Line

Proper Citation

RRID:CVCL_A4CJ

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A4CJ

Proper Citation: RRID:CVCL_A4CJ

Description: Cell line B16-F10-Luc2 [ATCC] is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Male

Disease: Mouse melanoma

Comments: Characteristics: Stably expresses firefly luciferase under the control of the human EF1a promoter (ATCC=CRL-6475-LUC2).

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: B16-F10-Luc2 [ATCC]

Cross References: ATCC:CRL-6475-LUC2, Wikidata:Q105506458

ID: CVCL_A4CJ

Hierarchy: cvcl_0159

Record Creation Time: 20220427T215231+0000

Record Last Update: 20260905T184708+0000

Ratings and Alerts

No rating or validation information has been found for B16-F10-Luc2 [ATCC].

No alerts have been found for B16-F10-Luc2 [ATCC].

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hu M, et al. (2026) Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity. *Cancer cell*, 44(5), 965.

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. *iScience*, 29(6), 115978.

Yan C, et al. (2026) RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance. *Nature communications*, 17(1), 162.

Kremmyda P, et al. (2026) SHP2 regulates VEGFR2 Y1175/PLC?? signaling to impair tumor endothelial barrier stability. *iScience*, 29(2), 114784.

Hoffmann J, et al. (2025) Steatohepatitis-induced vascular niche alterations promote melanoma metastasis. *Cancer & metabolism*, 13(1), 5.

Zhang FQ, et al. (2025) Zeaxanthin augments CD8+ effector T cell function and immunotherapy efficacy. *Cell reports. Medicine*, 6(9), 102324.

Shiralkar J, et al. (2024) Neural recordings can differentiate between spontaneously metastasizing melanomas and melanomas with low metastatic potential. *PloS one*, 19(2), e0297281.

Jiao M, et al. (2024) VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway. *iScience*, 27(7), 110285.

Yang Z, et al. (2024) Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. *Cancer cell*.